Evidence map›Paper›PMID 30189837›Full record

ArticleBMC cancer2018

Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.

Lenka Kalinkova, Iveta Zmetakova, Bozena Smolkova, Gabriel Minarik, Tatiana Sedlackova, Viera Horvathova Kajabova, Zuzana Cierna, Michal Mego, Ivana Fridrichova

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. miR-205-5p Downregulation andInternational journal of molecular sciences · 2021
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Lenka KalinkovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, v.v.i., Dubravska cesta 9, 845 05, Bratislava, Slovak Republic.
Iveta ZmetakovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, v.v.i., Dubravska cesta 9, 845 05, Bratislava, Slovak Republic.
Bozena SmolkovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, v.v.i., Dubravska cesta 9, 845 05, Bratislava, Slovak Republic.
Gabriel MinarikInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovak Republic.
Tatiana SedlackovaInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovak Republic.
Viera Horvathova KajabovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, v.v.i., Dubravska cesta 9, 845 05, Bratislava, Slovak Republic.
Zuzana CiernaInstitute of Pathological Anatomy, Faculty of Medicine, Comenius University, University Hospital, Sasinkova 4, 811 08, Bratislava, Slovak Republic.
Michal Mego2nd Department of Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, Klenova 1, 83310, Bratislava, Slovak Republic.
Ivana FridrichovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, v.v.i., Dubravska cesta 9, 845 05, Bratislava, Slovak Republic. ivana.fridrichova@savba.sk.ORCID http://orcid.org/0000-0001-7581-1770
Slovak Academy of Sciences · SKComenius University Bratislava · SKCancer Institute (WIA) · INInstitute of Chemistry of the Slovak Academy of Sciences · SK

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-0076-10Agentúra na Podporu Výskumu a Vývoja APVV-14-0327Agentúra na Podporu Výskumu a Vývoja APVV-16-0010European Fund for Regional Development through Operation Program of Research and Development ITMS 26240220058Vedecká Grantová Agentúra MŠVVaŠ SR a SAV VEGA 2/0092/15Vedecká Grantová Agentúra MŠVVaŠ SR a SAV VEGA 2/0102/17
6 · The paper itself

Abstract

backgroundIn breast cancer (BC), deregulation of DNA methylation leads to aberrant expressions and functions of key regulatory genes. In our study, we investigated the relationship between the methylation profiles of genes associated with cancer invasivity and clinico-pathological parameters. In detail, we studied differences in the methylation levels between BC patients with haematogenous and lymphogenous cancer dissemination.

methodsWe analysed samples of primary tumours (PTs), lymph node metastases (LNMs) and peripheral blood cells (PBCs) from 59 patients with sporadic disseminated BC. Evaluation of the DNA methylation levels of six genes related to invasivity, ADAM23, uPA, CXCL12, TWIST1, SNAI1 and SNAI2, was performed by pyrosequencing.

resultsAmong the cancer-specific methylated genes, we found lower methylation levels of the SNAI2 gene in histologic grade 3 tumours (OR = 0.61; 95% CI, 0.39-0.97; P = 0.038) than in fully or moderately differentiated cancers. We also evaluated the methylation profiles in patients with different cancer cell dissemination statuses (positivity for circulating tumour cells (CTCs) and/or LNMs). We detected the significant association between reduced DNA methylation of ADAM23 in PTs and presence of CTCs in the peripheral blood of patients (OR = 0.45; 95% CI, 0.23-0.90; P = 0.023).

conclusionThe relationships between the decreased methylation levels of the SNAI2 and ADAM23 genes and cancer de-differentiation and haematogenous dissemination, respectively, indicate novel functions of those genes in the invasive processes. After experimental validation of the association between the lower values of SNAI2 and ADAM23 methylation and clinical features of aggressive BCs, these methylation profiles could improve the management of metastatic disease.

Indexed as

DNA MethylationADAM ProteinsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCase-Control StudiesCell Line, TumorFemaleHumansMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingSnail Family Transcription FactorsADAM23 protein, humanADAM ProteinsBiomarkers, TumorSNAI2 protein, humanSnail Family Transcription FactorsADAM23 methylationBreast cancerCancer cell de-differentiationHaematogenous disseminationSNAI2 methylation

Identifiers

PMID30189837
PMCPMC6127923
OpenAlexW2890666911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.